Imagyn licenses MicroSpan line to Ethicon:
This article was originally published in Clinica
Executive Summary
Imagyn Medical Technologies is to license its MicroSpan microhysteroscopy product line to Ethicon. Under the terms of the agreement, which includes cash payments of $4 million with certain milestones, Imagyn, of Newport Beach, California, will initially supply the products to Ethicon for up to two years on an exclusive basis. Ethicon will have a worldwide, exclusive licence to manufacture and market the products for ten years. After this time, Somerville, New Jersey-based Ethicon will own the products. Imagyn recently announced the divestiture of its impotence product lines to Timm Research for $25.8 million. The company is looking at options - including sale or alliances - for its remaining non-strategic assets.
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.